119 related articles for article (PubMed ID: 11488730)
1. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder.
Røtterud R; Berner A; Holm R; Skovlund E; Fosså SD
BJU Int; 2001 Aug; 88(3):202-8. PubMed ID: 11488730
[TBL] [Abstract][Full Text] [Related]
2. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma.
Jahnson S; Karlsson MG
Cancer; 2000 Aug; 89(3):619-29. PubMed ID: 10931462
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53.
Ong F; Moonen LM; Gallee MP; ten Bosch C; Zerp SF; Hart AA; Bartelink H; Verheij M
Radiother Oncol; 2001 Nov; 61(2):169-75. PubMed ID: 11690683
[TBL] [Abstract][Full Text] [Related]
5. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
[TBL] [Abstract][Full Text] [Related]
7. Alterations affecting the p53 control pathway in bilharzial-related bladder cancer.
Osman I; Scher HI; Zhang ZF; Pellicer I; Hamza R; Eissa S; Khaled H; Cordon-Cardo C
Clin Cancer Res; 1997 Apr; 3(4):531-6. PubMed ID: 9815716
[TBL] [Abstract][Full Text] [Related]
8. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?
Steiner G; Bierhoff E; Schmidt D; Leissner J; Wolf HK; Albers P
Eur J Cancer; 2000 Mar; 36(5):610-4. PubMed ID: 10738125
[TBL] [Abstract][Full Text] [Related]
9. Cell cycle inhibitors and outcome after radiotherapy in bladder cancer patients.
Røtterud R; Pettersen EO; Berner A; Holm R; Olsen DR; Fosså SD
Acta Oncol; 2002; 41(5):463-70. PubMed ID: 12442923
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
11. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder.
El-Kenawy Ael-M; El-Kott AF; Khalil AM
Int J Biol Markers; 2003; 18(4):284-9. PubMed ID: 14756544
[TBL] [Abstract][Full Text] [Related]
13. p21 and p53 Immunostaining and survival following systemic chemotherapy for urothelial cancer.
Jankevicius F; Goebell P; Kushima M; Schulz WA; Ackermann R; Schmitz-Dräger BJ
Urol Int; 2002; 69(3):174-80. PubMed ID: 12372883
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.
Tuna B; Yörükoğlu K; Tüzel E; Güray M; Mungan U; Kirkali Z
Pathol Res Pract; 2003; 199(5):323-8. PubMed ID: 12908522
[TBL] [Abstract][Full Text] [Related]
15. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer.
Shariat SF; Tokunaga H; Zhou J; Kim J; Ayala GE; Benedict WF; Lerner SP
J Clin Oncol; 2004 Mar; 22(6):1014-24. PubMed ID: 14981102
[TBL] [Abstract][Full Text] [Related]
16. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
Craanen ME; Blok P; Offerhaus GJ; Meijer GA; Dekker W; Kuipers EJ; Meuwissen SG
J Pathol; 1999 Dec; 189(4):481-6. PubMed ID: 10629547
[TBL] [Abstract][Full Text] [Related]
17. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
[TBL] [Abstract][Full Text] [Related]
18. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2.
García JF; Piris MA; Lloret E; Orradre JL; Murillo PG; Martínez JC
Histopathology; 1997 Feb; 30(2):120-5. PubMed ID: 9067734
[TBL] [Abstract][Full Text] [Related]
19. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
20. Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
Pfister C; Larue H; Moore L; Lacombe L; Veilleux C; Tetu B; Meyer F; Fradet Y
Int J Cancer; 2000 Jan; 89(1):100-4. PubMed ID: 10719738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]